Further Studies on the Uptake of Synkavit and a Radioactive Analogue into Tumour Cells in Tissue Culture
Open Access
- 1 December 1970
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 24 (4) , 817-825
- https://doi.org/10.1038/bjc.1970.96
Abstract
In a previous paper, the exact conditions under which the radioactive drug 2-methyl-6,7-ditritio-1,4-naphthaquinol bis disodium phosphate could be selectively incorporated into HEp/2 cells were reported. This work has now been extended and suggests that the selective property associated with two human tumour cell lines established in culture, HEp/2 and HeLa, and two forms of mouse ascites tumour cells propagated in vivo, is a metabolic conversion of the drug (priming stage) to a form which can probably be freely incorporated by all cell types. It is suggested that the observed variations in uptake of label with changes in pH, cell concentration and the inorganic phosphate concentration of the medium indicate that the “priming” stage is critically dependent on the conditions of the experiment.Keywords
This publication has 3 references indexed in Scilit:
- Selective Uptake of A Radioactive Drug Into Human Tumour Cells Growing in Tissue CultureActa Radiologica: Therapy, Physics, Biology, 1969
- Labelled Compound Related to Synkavit and its Uptake in Certain Human Tumours Studied by Radio-Isotope ScanningActa Radiologica: Therapy, Physics, Biology, 1969
- Clinical Trial of Radiosensitizers, Including Synkavit and Oxygen Inhaled at Atmospheric PressureActa Radiologica: Therapy, Physics, Biology, 1965